APSR2026-940

 
Late-Breaking
Submitted
Oral Presentation
AO34-003
 
 
https://storage.unitedwebnetwork.com/files/1285/1242259-46903-APSR-940_439728.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Guijuan Ji - The Affiliated Hospital of Xuzhou Medical University Department of Respiratory and Critical Care Medicine Xuzhou China
Nan Sun - Xuzhou Medical University Cancer Institute, Cellular Therapeutics School of Medicine Xuzhou China
Bowen Lu * Xuzhou Medical University Cancer Institute, Cellular Therapeutics School of Medicine Xuzhou China
Haomin Chen - Xuzhou Medical University Cancer Institute, Cellular Therapeutics School of Medicine Xuzhou China
Yizhuo Ding - Xuzhou Medical University Cancer Institute, Cellular Therapeutics School of Medicine Xuzhou China
Bi Chen - The Affiliated Hospital of Xuzhou Medical University Department of Respiratory and Critical Care Medicine Xuzhou China
Dafei Chai - Xuzhou Medical University Cancer Institute, Cellular Therapeutics School of Medicine Xuzhou China
 
 
 
 
 
 
 
 
Presenting Author Details
Bowen
Lu
1634191161@qq.com
+8613815303765
41-50
China
Original Research
Non-functional PD-L1/Galectin-9 Adenoviral Vaccination Targets Immunosuppressive Feedback in Lung Cancer
Maximum 25 words
Abstract Content
Adaptive immune resistance mediated by PD-L1/PD-1 and Galectin-9/TIM-3 contributes to lung cancer immune escape.We investigated a non-functional dual-antigen adenoviral vaccine designed to remove immune-inhibitory function while preserving antigenicity. PD-L1/PD-1和Galectin-9/TIM-3介导的适应性免疫抵抗是肺癌免疫逃逸的原因之一。我们研究了一种非功能性双抗原腺病毒疫苗,该疫苗旨在去除免疫抑制功能,同时保留抗原性。
Secreted PD-L1 extracellular-domain antigen and Galectin-9 with key carbohydrate-recognition-domain mutations were generated to produce Ad-PD-L1(NF),Ad-Gal9(ΔCRD),and combined Ad-PD-L1(NF)/Ad-Gal9(ΔCRD) vaccines.Antigen expression,secretion and immunogenicity were assessed by flow cytometry,ELISA and western blotting.Neutralisation of PD-1/PD-L1 and Galectin-9/TIM-3 interactions was evaluated using immune sera.Antitumour efficacy was tested in Lewis lung carcinoma (LLC) and CMT167 murine subcutaneous,orthotopic and lung-metastasis models,with flow cytometry and immunohistochemistry used to profile the tumour immune microenvironment. 构建了分泌型PD-L1胞外结构域抗原和具有关键碳水化合物识别结构域突变的半乳糖凝集素-9,用于制备Ad-PD-L1(NF)、Ad-Gal9(ΔCRD)以及Ad-PD-L1(NF)/Ad-Gal9(ΔCRD)联合疫苗。采用流式细胞术、ELISA和Western blotting检测抗原表达、分泌和免疫原性。利用免疫血清评估PD-1/PD-L1和半乳糖凝集素-9/TIM-3相互作用的中和作用。在Lewis肺癌(LLC)和CMT167小鼠皮下、原位和肺转移模型中测试抗肿瘤疗效,并采用流式细胞术和免疫组织化学分析肿瘤免疫微环境。
PD-L1 and Galectin-9 were detected in lung cancer cell lines and tumour tissues,supporting dual-target intervention.The vaccines expressed the designed antigens and induced robust anti-PD-L1 and anti-Galectin-9 antibody responses.Sera from the combined-vaccine group simultaneously blocked PD-1/PD-L1 and Galectin-9/TIM-3 binding. Compared with single-target vaccination,combined vaccination significantly suppressed tumour growth and metastasis,prolonged survival,increased intratumoural CD8+ T-cell infiltration and IFN-γ/TNF-α expression,promoted dendritic-cell maturation,reduced regulatory T-cell (Treg) and myeloid-derived suppressor cell (MDSC) proportions,and decreased PD-1+TIM-3+ exhausted CD8+ T cells.No obvious weight loss or major-organ injury was observed. 在肺癌细胞系和肿瘤组织中检测到了PD-L1和Galectin-9,支持双靶点干预。疫苗表达了设计的抗原,并诱导了强烈的抗PD-L1和抗Galectin-9抗体反应。联合疫苗组的血清同时阻断了PD-1/PD-L1和Galectin-9/TIM-3的结合。与单靶点疫苗相比,联合疫苗显著抑制了肿瘤生长和转移,延长了生存期,增加了肿瘤内CD8+ T细胞浸润和IFN-γ/TNF-α表达,促进了树突状细胞成熟,降低了调节性T细胞(Treg)和髓源性抑制细胞(MDSC)的比例,并减少了PD-1+TIM-3+耗竭的CD8+ T细胞。未观察到明显的体重减轻或主要器官损伤。
A non-functional PD-L1/Galectin-9 dual-target adenoviral vaccine induced endogenous neutralising antibodies and disrupted two immunosuppressive checkpoint axes,thereby remodelling the tumour microenvironment and restoring CD8+ T-cell antitumour immunity.This approach may provide a translational active-immunisation strategy for overcoming immunotherapy resistance in lung cancer. 一种非功能性PD-L1/Galectin-9双靶点腺病毒疫苗诱导内源性中和抗体,并破坏了两个免疫抑制检查点通路,从而重塑肿瘤微环境并恢复CD8+ T细胞抗肿瘤免疫力。这种方法可能为克服肺癌免疫治疗耐药性提供一种转化型主动免疫策略。
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
 
maximum 3 keywords and no abbreviations, separated by commas
 
298